Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194478 | PMC |
| http://dx.doi.org/10.1093/ckj/sfae161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ApoE immunostaining has diagnostic utility in differentiating dense deposit disease and C3 glomerulonephritis: Clone-based evaluation of D719N, EP1373Y and 1B2C9.
Mod Pathol
August 2025
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Electron microscopy (EM) has been essential for the diagnosis of dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Recent research showed significantly higher accumulation of apolipoprotein E (ApoE) in DDD compared to C3GN and tested the use of ApoE immunohistochemistry for DDD diagnosis. We aimed to investigate the diagnostic value of ApoE in DDD and C3GN using three distinct ApoE clones, D719N, EP1373Y, and 1B2C9.
View Article and Find Full Text PDFStructural, functional and biochemical characterisation of apolipoprotein(a)-containing low-density lipoproteins.
J Colloid Interface Sci
August 2025
Biofilm - Research Center for Biointerfaces and Department of Biomedical Science, Faculty of Health and Society, Malmö University, 20506 Malmö, Sweden; Instituto Biofisika (UPV/EHU, CSIC)) and Fundación Biofísica Bizkaia/Biofisika Bizkaia Fundazioa (FBB), University of the Basque Country, 48940
Atherosclerosis is the leading cause of cardiovascular diseases and remains a global health challenge. Low-density lipoproteins are crucial in atherogenesis, with plasma levels as significant independent predictors of the condition. Lipoprotein(a), Lp(a), is an LDL variant considered a stand-alone atherosclerosis predictor.
View Article and Find Full Text PDFEstimated Small, Dense LDL Cholesterol and Atherosclerotic Cardiovascular Risk in the UK Biobank.
Arterioscler Thromb Vasc Biol
August 2025
Lipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. (R.Z., A.W., A.T.R.).
Background: A key step in primary prevention is the assessment of atherosclerotic cardiovascular disease (ASCVD) risk. Risk enhancer tests are additional tools used to further improve ASCVD risk assessment over conventional risk markers. Our objective was to determine whether estimated small, dense low-density lipoprotein cholesterol (E-sdLDL-C) can improve risk assessment and serve as a new risk enhancer test.
View Article and Find Full Text PDFElevated small dense low-density lipoprotein-cholesterol as a risk factor for lower extremity arterial disease in patients with type 2 diabetes mellitus.
J Diabetes Complications
October 2025
The Operative Surgery Laboratory, Bengbu Medical University, China.
Aims: Small dense low-density lipoprotein-cholesterol (sdLDL-C) is an emerging atherogenic lipid marker, but its association with lower extremity arterial disease (LEAD) in type 2 diabetes mellitus (T2DM) remains underexplored. This study aimed to evaluate whether sdLDL-C independently predicts LEAD risk in T2DM patients.
Methods: A cross-sectional study was conducted with 47 healthy controls, 66 T2DM patients, and 120 patients with both T2DM and LEAD.